MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
09/18/17MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America’s 21st Annual Scientific Meeting
NASDAQ GS | MYOK (Common Stock)
$36.95 - 0.9
10/20/174:03 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.